Kornimate/medical-research-clean huggingface dataset:
pilot study assessing the effects of pxt00864 in patients with mild alzheimer disease (ad)

Conditions: Alzheimer Disease

Summary: the purpose of this study is to assess the safety and efficacy on cognitive impairment and functioning of several doses of pxt00864 (new fixed combination of acamprosate and baclofen at low dose) in patients with mild alzheimer disease.


Eligibility criteria:
inclusion criteria: * male or female patients aged ≥ 60 years. * patient with a diagnosis of probable ad * progressive decline in cognition for more than six months which story is documented in patient medical records * a mini-mental state examination (mmse) score of 20-26 * with a minimum of educational background * naïve to anti-dementia treatment * mri assessment which corroborates the clinical diagnosis (hippocampal atrophy) and excludes other potential causes of dementia especially cerebrovascular lesions * if available, cerebral spinal fluid (csf) classical biomarkers should be at levels which corroborate the clinical diagnosis * ambulatory patient living at home with a caregiver available and living in the same household or interacting with the patient daily and available if necessary to ensure administration of the investigational product * absence of major or severe depressive disease * patient with a willingness to participate in this study and who have signed an informed consent form exclusion criteria: * early onset of dementia, i.e. before 60 years old to avoid hereditary ad forms * significant neurological disease other than ad * major psychiatric disorder or syndrome (schizophrenia or bipolar disorder) * seizure disorders * other infectious, metabolic or systemic diseases affecting central nervous system * other active clinically significant illness * hospitalization or change of chronic concomitant medications one month prior to screening * patients with severe respiratory, hepatic or renal failure or with any other significantly potentially disabling abnormality detected during screening * known hypersensitivity to the tested treatment including active substance and excipients. * patients participating in another study and exposed to any investigational therapy within the 30 days prior to the entry in this study. * patient without medical care insurance

Keywords: pxt00864 mild ad phase 2a
subsequent bevacizumab treatment in patients with hht. follow up babh

Conditions: Hemorrhagic Hereditary Telangiectasia; HHT

Summary: bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in hht. we studied the efficacy of bevacizumab on severe bleeding in hht patients in a randomized study recently published (nct03227263, j int med 2023). in this study, 24 patients were included, 12 patients received bevacizumab and 12 patients received placebo. the duration of patient participation was 6 months, including the 2.5-month treatment period and 3.5 month follow-up after treatment. we describe the evolution of the number of rbc transfused in hht patients who received bevacizumab during the year after the end of the study.


Eligibility criteria:
inclusion criteria: * patient included in babh study exclusion criteria: * patients opposition

Keywords: hht vegf therapy bevacizumab
a clinical study to assess the natural history of covid-19 and effects of kb109 and supportive self-care in outpatients with mild-to-moderate covid-19

Conditions: Mild-to-moderate COVID-19

Summary: this randomized, open-label, prospective, parallel-group controlled clinical study that aims to explore the natural history of covid-19 illness and the safety of kb109, a novel glycan, plus ssc versus ssc alone and measures of health in outpatients with mild-to-moderate covid-19.


Eligibility criteria:
inclusion criteria: * be male or female, ≥18 years of age * be willing and able to give informed consent * screening/randomization telemedicine visit within 2 days of testing positive test for covid-19 * having self-reported fever or cough for not more than 72 hours prior to covid-19 testing * mild to moderate covid-19 * able to adhere to the study visit schedule and other protocol requirements. exclusion criteria: * patients who are hospitalized for in-patient treatment or currently being evaluated for potential hospitalization at the time of informed consent for conditions other than covid- 19 * history of chronic lung disease * ongoing requirement for oxygen therapy * shortness of breath in resting position * diagnosis of sleep apnea requiring bilevel positive airway pressure (bipap) / continuous positive airway pressure (cpap) * female patients who are pregnant, trying to become pregnant or lactating * is considered, in the opinion of the pi, to be unlikely for any reason to be able to comply with study procedures

Keywords: microbiome covid-19 corona virus corona virus disease kaleido kaleido biosciences kb109 oligosaccharide glycan pathogens microbiome metabolic therapy mmt supportive self care ssc telemedicine
combination of continuous femoral block and intravenous parecoxib for postoperative analgesia after total knee arthroplasty

Conditions: POSTOPERATIVE ANALGESIA FOR TKA PARECOXIB/CFB

Summary: combination of continuous femoral block with parecoxib vs placebo. investigation of morphine consumption, opioid sparing effects, vas pain scores, haemodynamics, anxierty scores, transfusion requirements , range of motion and rehabilitation parameters between two groups


Eligibility criteria:
inclusion criteria: * patients asa i-ii undergoing total knee atrthroplasty exclusion criteria: exclusion criteria for both groups included: * age younger than 40 years old or older than 80 years old * asa \> iii * obesity (\>140 kg body weight) * allergy to local anesthetics * history dependence on opioids * contraindications for subarachnoid anesthesia or femoral block (coagulopathy, local infection, pre-existing neurological problems, patient refusal) * contraindications to the administration of parecoxib * severe hepatic or renal disease (serum creatinine ≥ 1.7 mg/dl)

Keywords: parecoxib continuous femoral block
comparison of the effects of retro laminar block (rlb) and erector spina area block (esp) on postoperative recovery quality and pain in lumbar spinal surgery

Conditions: Postoperative Pain

Summary: the aim of this study is to compare the efficacy of erector spinae plane block (espb) and retrolaminar block on postoperative recovary quality and pain after lumbar spinal surgery

the study was designed as a double-blind, prospective randomized controlled trial. blindness; the healthcare professionals who will monitor the patient's pain in the post-operative period will not know which of the esp or rlb block is applied. randomization of the patients was planned using computer aided. it was envisaged to include 40 participants each in the esp block and rlb block groups. the current pain status of the patients in the esp block and rlb block groups in the postoperative period was determined by nrs (numerical rating scale) at rest and motion at certain hour intervals (30 .min,1.,6.,12.,24. hours) will be done, when the patients' nrs scores are 4 and above, an additional intravenous analgesic will be administered and the number of bolus doses with pca in the first 24 hours will be recorded. the recovery quality of the patients who underwent both esp block and rlb block at the postoperative 24th hour will be evaluated with a (qor-40) scoring system. in addition, the hemodynamic values of the patients will be recorded in these intervals.

Eligibility criteria:
inclusion criteria: * patients undergoing lumbar spinal surgery under elective conditions * asa i-iii * between 18-75 ages exclusion criteria: * refuse during registration * request to be dismissed from study * failure to give informed consent * emergency surgery * bleeding diathesis * presence of contraindications to the la agents used in this study chronic use of opioids psychiatric disorders the presence of infection at the injection site

Keywords: recovery quality postoperative pain erector spina plane block retrolaminar block
comparison of karydakis and limberg flap treatment of pilonidal sinus in adolescent. a prospective, randomised study

Conditions: Pilonidal Sinus; Postoperative Complications

Summary: pilonidal sinus disease (psd) is a chronic inflammation and infection of the sacrococcygeal region. produces clinic findings with abscess and discharge in the sacrococcygeal region or painful sinus tract in the natal cleft. its incidence rate among turkish servicemen is reported to be 8.8% in a study. although pilonidal sinus disease is common in men, this is the opposite in adolescence. because adolescent girls are 2 or 3 times more. karydakis flap and limberg flap operations widely preferred in recent years in the surgical treatment of psd. in our study, we aim to compare these two techniques prospectively and randomly.

the best treatment technique for pilonidal sinus disease (psd) is still controversial. while some researchers prefer minimally invasive methods, some researchers prefer surgical treatment. the most important concern in surgical treatment options is the prolongation of the disease recovery time and recurrence of the disease. complications that may develop after treatment prolong the treatment period. the aim of this prospective, randomized study was to compare the results of the widely used limberg and karydakis flap operations in recent years. the parameters that will be used in the comparison will be an infection, recurrence and wound decomposition.

Eligibility criteria:
inclusion criteria: * pilonidal sinus disease exclusion criteria: * other disease than pilonidal sinus disease.

Keywords: pilonidal sinus presakral apse limberg flap karydakis flap
sevoflurane versus desflurane for catheter-related bladder discomfort

Conditions: Catheter Site Discomfort; Complications; Anesthesia; Urinary Bladder Neoplasms

Summary: we want to evaluate the efficacy of the sevoflurane and desflurane for the prevention of catheter-related bladder discomfort.

the mechanism of catheter-related bladder discomfort is thought to be related to the muscarinic receptor. the volatile anesthetics such as sevoflurane and desflurane are known to block the muscarinic receptor in different ways. we want to evaluate the efficacy of the sevoflurane and desflurane for the prevention of catheter-related bladder discomfort.

Eligibility criteria:
inclusion criteria: * patients scheduled for transurethral bladder excision under general anesthesia * asa i-iii exclusion criteria: * bladder outflow obstruction * overactive bladder * end-stage renal disease * neurogenic bladder * heart failure * arrhythmia * morbid obesity * use of chronic analgesic medication * hepatic disease * pulmonary disease * psychiatric disease
guided radiofrequency ablation using the carto® 3 and navx™ systems for the treatment of paroxysmal atrial fibrillation

Conditions: Paroxysmal Atrial Fibrillation

Summary: the purpose of this study is to determine the change in median radiation exposure time and median procedure time following guided radiofrequency (rf) ablation among subjects undergoing treatment for paroxysmal atrial fibrillation with either the carto® 3 or the navx(tm) system. it is hypothesized that described features will reduce the median radiation exposure during the carto® 3 system-guided procedures compared to the navx(tm) system-guided procedures.


Eligibility criteria:
inclusion criteria: * all patients referred for a first radiofrequency ablation procedure for treatment of paroxysmal atrial fibrillation (af episodes that last less than 30 days and are not terminated via cardioversion) and who are considered eligible for treatment by the physician. exclusion criteria: * there are no study specific exclusion criteria for this observational study. the exclusion criteria will be conditions that, in the physicians opinion, preclude an rf ablation procedure because the procedure risks outweigh any potential benefits for the subject.
using iron with procrit in advanced lung cancer patients with chemotherapy-induced anemia

Conditions: Anemia

Summary: the purpose of this study is to find a better, more convenient way to improve anemia results by increasing the amount of medication given at 3 week intervals. researchers want to know if giving a higher dose of procrit® and intravenous (iv) iron once every 3 weeks would give better results in treating anemia without the need for more office visits.

there are more than 170,000 patients diagnosed with lung cancer in the united states each year and many will develop anemia (iron deficiency) during the course of treatment. anemia is associated with poor quality of life and treatment delays for advanced lung cancer. the treatment of iron deficiency anemia is with iron. iron is an essential mineral used in red blood cells to carry oxygen throughout the body. iron is necessary to make hemoglobin, a key element in red blood cells. the fda has approved procrit® (epoetin alfa) to treat anemia in people with non-myeloid (bone marrow) malignancies. procrit® is a man-made, injectable drug for treating anemia and it encourages red cell production. while the administration of intravenous iron therapy, injected into veins through an iv, did increase the response rate of procrit® in a previous study, researchers want to find out the best amount of drug to use and the best time to administer procrit®, along with ferric gluconate, (ferrlecit®), added for lack of iron.

Eligibility criteria:
inclusion criteria: * histologically confirmed small cell or non small cell lung cancer * stage iii or stage iv lung cancer * platinum containing chemotherapy induced anemia (\< 10 g/dl hb) * cancer related anemia (\<10 g/dl hb) at time of initiation of chemotherapy * ecog performance status of 0,1, or 2 * informed consent * age\>18 * expected to receive platinum based outpatient chemotherapy for at least nine weeks exclusion criteria: * pregnant women * intolerance to epoetin alfa or parenteral iron * more than 2 cycles of the planned platinum chemotherapy at time of enrollment * chronic gi bleed (\> than 4 weeks positive hemoccult or gastroccult) * ferritin \> 500 mg/dl * anemia due to other causes than cancer or chemotherapy * previous parenteral iron therapy * uncontrolled hypertension (systolic bp \> 160, diastolic \> 100 mmhg)

Keywords: advanced lung cancer procrit epoetin alfa ferric gluconate iron supplementation
cell-free fetal dna concentration in cases of abnormal placental invasion .

Conditions: Placenta Accreta; Placenta Percreta; Placenta Increta; Placenta Previa

Summary: cell free fetal dna might predict abnormal placental invasion

this study aims to evaluate whether measurement of cell-free fetal dna in the maternal plasma can be predictive of abnormal invasion in cases of placenta previa.

Eligibility criteria:
inclusion criteria: 1. maternal age range from 20-40 years old. 2. parity: para 1- para 5. 3. body mass index range from 18-25 kg/m2. 4. singleton pregnancy carrying male fetuses. 5. gestational age range from 28-34 weeks. exclusion criteria: 1. multifetal pregnancy. 2. hypertension, preterm labor and intrauterine growth restriction. 3. patients taking a tocolytic agent or those with uterine bleeding at or after blood sampling. * since these complications may increase the level of cell-free fetal dna. 4. accidental hemorrhage.
safety and efficacy of pulmonary vein isolation using pulsed-field ablation (pfa) combined with either pfa-based left atrial posterior wall isolation or vein of marshall ethanol ablation in patients with persistent atrial fibrillation

Conditions: Atrial Fibrillation (AF)

Summary: this study is designed to directly compare the safety and efficacy of pfa-based pvi+pwi vs pfa-based pvi+ vom alcohol ablation in patients with persistent af.


Eligibility criteria:
inclusion criteria: * symptomatic persistent af; 1st or redo ablation with pvi-only in the earlier procedure * willing to provide informed consent * age: 18-85 years exclusion criteria: * • previous pwi or vom ablation procedure * left ventricular ejection fraction \<40% * left atrial thrombus * myocardial infarction within last 60 days * cardiac surgery in the last 6 months * advanced renal failure * life expectancy \<1 year * pregnant women * unable or unwilling to provide informed consent

Keywords: persistent af
effectiveness of virtual reality on functional mobility during treadmill training in children with cerebral palsy

Conditions: Cerebral Palsy, Spastic

Summary: cerebral palsy (cp), which occurs as a consequence of brain damage, has multiple deficits such as a global reduction of motor cortical activity during movement execution and inadequate processing of corticospinal and somatosensory circuits. global registers estimate that it occurs in two to three of 1.000 live births, and spasticity is the most common disorder, occurring in 80% of children with cp. spasticity might affect both upper and lower limbs, resulting in other deficits in joint mobility, postural reactions, selective motor control, balance, and gait. this set of impairments and deficits may lead to limitations in functional ability and autonomy in the performance of daily living activities, physical fitness, quality of life, and/or ability to participate in games and sports activities compared to neurotypical peers of the same age. walking is considered one of the most important activities in daily life, as it is essential for activities of daily living and social participation. children with gross motor function classification system (gmfcs) levels i, ii, and iii show potential for walking, and around 75% of cp children are ambulatory. however, abnormalities in neural control and muscle weakness contribute to several gait characteristics such as slow velocity, decreased stride length, increased stance phase percentage, and increased peak ankle dorsiflexion and knee flexion, and peak hip extension moments. consequently, this gait pattern contributes to postural instability and increased fall risk in children with cp, among others.

the main objective of the present study is to evaluate the effectiveness of treadmill gait training and virtual reality comparing to treadmill gait training on functional mobility in infants with spastic cerebral palsy. the study design is a two-arm randomized clinical trial, single-center and single-blind (evaluators). the sample will be recruited at the hospital general de vic, and the study will be conducted at the universitat de vic - universitat central de catalunya (uvic-ucc).

Eligibility criteria:
inclusion criteria: * medical diagnosis of spastic cerebral palsy * motor function levels i to iii according to the gross motor function classification system * independent walking was acquired for more than 12 months. * able to ambulate for at least 10 meters with or without aids. exclusion criteria: * orthopaedic surgery on the lower limbs in the past 12 months. * scheduled surgery during the period of the study. * orthopaedic deformities with surgery indication. * uncontrolled seizure disorder. * metallic implant in the skull. * hearing aid. * have received toxic botulin injections in the past 6 months. * significant cognitive or visual impairment.

Keywords: "rehabilitation"[mesh] "mobility limitation"[mesh] "virtual reality"[mesh]
a study of opportunistic salpingectomy to prevent ovarian cancer

Conditions: Surgery

Summary: the purpose of this study is to find out how many participants are interested in a surgical preventive procedure after watching an educational video. before and after watching the video, participants will complete questionnaires in the clinic.


Eligibility criteria:
inclusion criteria: part i * age ≥45 years * scheduled visit with a nongynecologic surgeon * female or assigned female at birth part ii * age ≥45 years * at least one in situ fallopian tube * no desire or plan to have children in the future * average risk of developing ovarian cancer ° note: average risk patients are defined as patients with no known genetic risk factor for developing ovarian cancer. patients who, after obtaining family history, are suspected to have a hereditary ovarian cancer syndrome but have not yet been tested, will be referred for genetic evaluation. * planned nongynecologic, intraabdominal, or pelvic surgery * deemed to be a suitable candidate by gynecologic surgeon and primary nongynecologic surgeon (for example, on the basis of surgical history and current malignancy status) * approved and signed informed consent exclusion criteria: part i * not fluent in english ° if there is a non-english speaking participant who is a strong candidate and meets all other criteria for part 2, they are able to go directly onto part 2 without completing part 1. (please see additional details in section 4.1 and 7.0.) * known inherited ovarian cancer susceptibility part ii * personal history of a gynecologic malignancy * carrier of a hereditary breast or ovarian cancer variant (e.g., brca1, brca2, brip1, palb2, rad51c, rad51d, mlh1, msh2, msh6, pms2) * suspicious ovarian, fallopian tube, or uterine lesion on preoperative imaging * previous bilateral salpingectomy or bilateral salpingo-oophorectomy * current pregnancy * emergent procedure or emergency procedure that has to be completed within 24 hours where clinical consent occurs in the inpatient setting or where the patient's immediate well-being is in danger or condition may be life threatening * primary surgeon anticipates that os will add significant time (\>30-40min) to the planned procedure. * inability to access the pelvis (ex., patient prone/lateral position) during the planned procedure. * known history of pelvic fibrosis or significant adhesions. * procedures with palliative intent only

Keywords: abdominal surgery pelvic surgery opportunistic salpingectomy ovarian cancer prevention 24-006 memorial sloan kettering cancer center
efficacy of mechanical traction and spinal decompression treatments in patients with low back pain

Conditions: Low Back Pain; Lumbar Disc Disease; Lumbar Disc Herniation; Lumbar Radiculopathy; Physical Therapy

Summary: motorized traction and non-surgical spinal decompression treatments are relatively new treatments for which there is insufficient evidence in the literature. in this study investigators aimed to retrospectively compare the effectiveness of these treatments, which are in the field of their routine practice in their clinic.

low back pain is one of the leading causes of disability worldwide. people with physically demanding jobs, physical and mental comorbidities, smokers, and obese individuals are at greater risk for low back pain. anatomical structures that potentially nociceptive contributors to low back pain are intervertebral discs, facet joints, and vertebral end plates. it has been determined that nonsurgical treatments are clinically effective in reducing pain and functional improvement in patients with lumbar disc herniation. however, the level of evidence has generally not been highly evaluated, which can be attributed to the paucity of well designed randomized controlled trials. despite moderate evidence, exercise and traction are recommended. in this study investigators aimed to retrospectively compare the effectiveness of these treatments, which are in the field of their routine practice in their clinic. 01.01.2019-10.11.2022. investigators planned to examine the records of patients aged 20-75 years who underwent physical therapy with the diagnosis of lumbar discopathy in afsu ftr department physical therapy unit. investigators planned to examine the routine anamnesis examination, treatment card and control evaluation records of the patients made in the ftr outpatient clinic from the automation system of their hospital.

Eligibility criteria:
inclusion criteria: * patients diagnosed with lumbar disc disorders * patients diagnosed with lumbar vertical hernia * aged 20-75 years exclusion criteria: * patients treated for acute low back pain * patients with a history of lumbar surgery * patients with spondylolisthesis or spinal stenosis * those with inflammatory rheumatic diseases (ankylosing spondylitis, spondylarthropathy etc.) * patients with sequestered hernia * patients with insufficient data in the records